Yazar "Sutcu, Mustafa" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    ORBITAL VENOUS MALFORMATION COMPLIATING WITH PERGNANCY: CASE REPORT
    (Medknow Publications & Media Pvt Ltd, 2012) Karamese, Mehtap; Selimoglu, M. Nebil; Toksoz, Mustafa Rasid; Sutcu, Mustafa; Keskin, Mustafa
    Introduction: One of the reason of orbital masses are vascular malformation. Vascular malformation grows up during pregnancy. Case: Here, we presented a 32-years-old patient with venous hemangioma which became symptomatic during pregnancy and required surgical intervention. Conclusion: In this case, we discussed here the terminology of venous malformation and cavernous hemanjioma. Progress and treatment of venous malformations during pregnancy are also discussed.
  • Küçük Resim Yok
    Öğe
    The Role of Stem Cells Derived From the Mesenchyme of the Umbilical Cord in Reducing Immunosuppressive Drug Doses Used in Allogenic Transplantations
    (Lippincott Williams & Wilkins, 2022) Evin, Seyda Guray; Sutcu, Mustafa; Aktan, Tahsin Murad; Duman, Selcuk; Harmankaya, Ismail; Abusoglu, Sedat
    BackgroundThis study evaluated the potential of Wharton's jelly mesenchymal stem cells with high tolerogenic properties in reducing immunosuppressive dosage and related adverse effects.MethodsA 4- to 6-week-old, 30-40 g weight, male inbred CD57BL/6 mice were used as skin allograft donors, whereas Balb/c mice with similar characteristics were used as recipients. Wharton's jelly stem cells were obtained from a commercial kit sourced from human umbilical cord. Skin allografts were performed from CD57Bl6 to Balb/c mice (day 0). Group 1 (control) received no treatment. Group 2 received 15 mg/kg cyclosporin A on days 0 to 30. Group 3 received 5.7 x 10(6) and 10.3 x 10(6) cell/kg Wharton's jelly stem cells on days 0 and 3, respectively. Groups 4, 5, and 6 received a combination of 15, 10, and 5 mg/kg per day cyclosporine A (days 0 to 30) with the same stem cell dose with group 3, respectively. Graft rejection was evaluated with digital photography and thermal imaging, histopathology (Banff grading, epithelialization scores, dermoepidermal dissociation), immunochemistry (Ki-67 and Bcl-2), and biochemical methods (interleukin 10, interleukin 2, interferon gamma, tumor necrosis factor alpha) (day 10). Cumulative adverse effects of cyclosporin A occurring in the groups were revealed by histopathological evaluation of kidney and liver (a modified semiquantitative method of infiltration of inflammatory cells around the portal area and lobular region in liver; modification of the Banff rating of proximal tubules and hypertrophia of juxtaglomerular apparatus cells in kidney) (day 30).ResultsThere was no rejection in groups 2, 4, and 5 until the end of study. These were statistically different versus groups 1 (day 10 +/- 0.71), 3 (day 11 +/- 0.82), and 6 (day 11 +/- 0.58) (all P's < 0.05). Groups 4 and 5 have exhibited statistically similar findings in histopathological (4 epithelization score: 3.7 +/- 1.3; 5 epithelization score: 3.5 +/- 0.5; 4 Banff grading score: 0.8 +/- 0.6; 5 Banff grading score: 1.0 +/- 0.5; both P's = 1.00), immunohistochemical (4 Bcl-2 score: 3.5 +/- 0.5, P = 0.618; 5 Bcl-2 score: 3.4 +/- 0.5, P = 1.00; 4 Ki-67 score: 3.7 +/- 0.4, P = 1.00; 5 Ki-67 score: 3.5 +/- 0.5, both P's = 1.00), and levels of cytokines (both P's = 1.00) versus group 2. Adverse effects on kidneys and liver were lowest and statistically similar in groups 3, 5, and 6 (all P's = 00) versus group 1.ConclusionsWharton's jelly mesenchymal stem cells alter bioavailability of cyclosporine, albeit at much lower doses and with fewer systemic adverse effects.